Unknown

Dataset Information

0

Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma.


ABSTRACT: Non-muscle invasive bladder cancer (NMIBC) has traditionally been managed with transurethral resection followed by intravesical chemotherapy and/or bacillus Calmette-Guerin (BCG) in a risk-adapted manner. These tumors commonly recur and can progress potentially to lethal muscle invasive disease. A major unmet need in the field of NMIBC is bladder preserving therapy for recurrent high-grade NMIBC after adequate intravesical BCG therapy. The current gold standard treatment for these BCG-unresponsive patients is radical cystectomy, which is associated with considerable morbidity and mortality, particularly in older and frailer patients. It is therefore critical to provide alternative treatment options with acceptable oncological outcomes. In this review we explore novel bladder-sparing treatment options including combination intravesical therapy, enhanced instillation methods, immunotherapy, gene therapy, targeted therapy, photodynamic therapy and BCG variants across the spectrum of NMIBC disease states, ranging from low grade BCG-naïve patients through to high-grade BCG-unresponsive NMIBC.

SUBMITTER: Yassaie O 

PROVIDER: S-EPMC8366114 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4714663 | biostudies-other
| S-EPMC5929349 | biostudies-other
| S-EPMC8215888 | biostudies-literature
| S-EPMC4872187 | biostudies-literature
| S-EPMC6925814 | biostudies-literature
| S-EPMC7722798 | biostudies-literature
| S-EPMC5809922 | biostudies-literature
| S-EPMC7193093 | biostudies-literature
| S-EPMC6966549 | biostudies-literature
| S-EPMC6386996 | biostudies-literature